Peroxisome proliferator-activated receptor-α: Friend or foe?

Hypertension

Volumn 50, Issue 5, 2007, Pages 847-850

  Yagil, Chana ^a   Yagil, Yoram ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCOSAHEXAENOIC ACID; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ROSIGLITAZONE;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL DIFFERENTIATION; CELL METABOLISM; FATTY ACID OXIDATION; FOLLOW UP; HUMAN; HYPERTENSION; LIPID METABOLISM; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; GENETICS; MOUSE; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; DOCOSAHEXAENOIC ACIDS; HUMANS; HYPERTENSION; MICE; MICE, TRANSGENIC; PPAR ALPHA; PROCETOFEN; RATS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 35848950945     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.100461     Document Type: Note

References (12)

1. Tordjman K, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, Vechoropoulos M, Stern N. Absence of peroxisome proliferatoractivated receptor-α abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension. 2007;50:945-951.
2. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 2001;107:1025-1034.
3. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518-533.
4. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPAR{alpha} activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866-871.
5. Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, Kroetz DL. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Proc Soc Exp Biol Med. 1999;221:32-38.
6. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-{alpha} activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005;46:366-371.
7. Prisco D, Paniccia R, Bandinelli B, Filippini M, Francalanci I, Giusti B, Giurlani L, Gensini GF, Abbate R, Neri Serneri GG. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res. 1998;91:105-112.
8. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34:253-260.
9. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004;36:295-304.
10. De Ciuceis C, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL. Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br J Pharmacol. 2007;151:45-53.
11. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL. Peroxisome proliferator-activated receptor-{alpha} and receptor-{gamma} activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension. 2003;42:737-743.
12. Subramanian S, DeRosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, Cryer PE, Semenkovich CF. PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab. 2006;291:E1365-E1371.